Short Interest in Eterna Therapeutics Inc. (NASDAQ:ERNA) Rises By 6.5%

Eterna Therapeutics Inc. (NASDAQ:ERNA) was the recipient of a large increase in short interest during the month of November. As of November 15th, there was short interest totalling 47,400 shares, an increase of 6.5% from the October 31st total of 44,500 shares. Currently, 0.2% of the shares of the company are short sold. Based on an average trading volume of 90,600 shares, the short-interest ratio is currently 0.5 days.

Eterna Therapeutics Stock Performance

NASDAQ:ERNA opened at $0.36 on Wednesday. The firm’s 50-day moving average is $0.91 and its 200-day moving average is $1.49. Eterna Therapeutics has a 52-week low of $0.36 and a 52-week high of $2.63. The company has a market cap of $1.95 million, a price-to-earnings ratio of -0.04 and a beta of 4.18.

About Eterna Therapeutics

Eterna Therapeutics Inc, a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited.